Compare ARK Genomic Revolution ETF (ARKG) vs Fox Corp Class B (FOX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Fox Corp Class B — how do they compare? ARK Genomic Revolution ETF trades at $41, while Fox Corp Class B trades at $49.17 (market cap $21.54B). The key difference: Fox Corp Class B pays a 1.15% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Fox Corp Class B nearer its low. Which is the better fit depends on your goals.
| ARKG | FOX | |
|---|---|---|
Sector | Sector/Thematic | Media |
52-Week High | $43.57 | $67.76 |
52-Week Low | $23.09 | $44.39 |
Market Cap | — | $21.54B |
Enterprise Value | — | $25.51B |
Dividend Yield | — | 1.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
FOX stock trades at $48.75, up 0.64% today, amid a bearish technical signal but strong fundamental performance. Recent quarters show consistent earnings beats, with Q2 2026 EPS expected at $1.41. The company's 2025 revenue surged to $16.3B, driving net income to $2.26B, while cash flow turned positive at $1.03B. Key developments include the $22B Roku acquisition, highlighting strategic moves in streaming, though leverage concerns have pressured the stock, which is down 25% over four weeks as of June 26, 2026 (Zacks Investment Research).
The outlook balances robust fundamentals against near-term headwinds. Valuation appears attractive with a P/E of 12.83 and EV/EBITDA of 8.19, but integration risks from the Roku deal and bearish technical trends pose challenges. Analyst consensus is mixed (42.86% Buy, 47.62% Hold), suggesting cautious optimism for long-term growth driven by streaming expansion and advertising recovery, though volatility may persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →
